Evidence map›Paper›PMID 32272891›Full record

SynthesisBMC gastroenterology2020

Statin and the risk of hepatocellular carcinoma in patients with hepatitis B virus or hepatitis C virus infection: a meta-analysis.

Xiaofei Li, Lina Sheng, Liwen Liu, Yongtao Hu, Yongxin Chen, Lianqing Lou

Open access · goldAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 6 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 6 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. A Meta-Analysis of Statin Use and Risk of Hepatocellular Carcinoma.Canadian journal of gastroenterology & hepatology · 2022
    Pooled it
  6. Pooled it
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Xiaofei LiDepartment of infectious diseases, Yiwu Central Hospital, No. 519 Nanmen Street, Yiwu, 322000, China. metshep@sina.com.
Lina ShengDepartment of infectious diseases, Yiwu Central Hospital, No. 519 Nanmen Street, Yiwu, 322000, China.
Liwen LiuDepartment of infectious diseases, Yiwu Central Hospital, No. 519 Nanmen Street, Yiwu, 322000, China.
Yongtao HuDepartment of infectious diseases, Yiwu Central Hospital, No. 519 Nanmen Street, Yiwu, 322000, China.
Yongxin ChenDepartment of infectious diseases, Yiwu Central Hospital, No. 519 Nanmen Street, Yiwu, 322000, China.
Lianqing LouDepartment of infectious diseases, Yiwu Central Hospital, No. 519 Nanmen Street, Yiwu, 322000, China.
Yichang Central People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStatin may confer anticancer effect. However, the association between statin and risk of hepatocellular carcinoma (HCC) in patients with hepatitis B virus (HBV) or hepatitis C (HCV) virus infection remains inconsistent according to results of previous studies. A meta-analysis was performed to summarize current evidence.

methodsRelated follow-up studies were obtained by systematic search of PubMed, Cochrane's Library, and Embase databases. A random-effect model was used to for the meta-analysis. Stratified analyses were performed to evaluate the influences of study characteristics on the outcome.

resultsThirteen studies with 519,707 patients were included. Statin use was associated with reduced risk of HCC in these patients (risk ratio [RR]: 0.54, 95% CI: 0.44 to 0.66, p < 0.001; I

conclusionsSatin use was independently associated with a reduced risk of HCC in patients with HBV or HCV infection.

Indexed as

Carcinoma, HepatocellularHepatitis B, ChronicHepatitis C, ChronicHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLiver NeoplasmsModels, StatisticalOdds RatioRisk FactorsTreatment OutcomeHydroxymethylglutaryl-CoA Reductase InhibitorsCirrhosisHepatitis B virusHepatitis C virusHepatocellular carcinomaMeta-analysisStatin

Identifiers

PMID32272891
PMCPMC7147033
OpenAlexW3015876750

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.